Antidepressants and bleeding risk after face-lift surgery.

Sanaz Harirchian, Richard A Zoumalan, David B Rosenberg
{"title":"Antidepressants and bleeding risk after face-lift surgery.","authors":"Sanaz Harirchian,&nbsp;Richard A Zoumalan,&nbsp;David B Rosenberg","doi":"10.1001/archfacial.2012.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the rate of post-face-lift hematoma among users of serotonin reuptake inhibitors (SSRIs) vs non-SSRI users. Selective serotonin reuptake inhibitors have come under recent scrutiny because of possible bleeding risks. However, cessation of SSRIs carries inherent risks.</p><p><strong>Methods: </strong>The medical charts for 250 consecutive patients who underwent a modified deep-plane face-lift and 13 patients who underwent neck-lift from January 2010 to May 2011 were reviewed for the incidence of postoperative hematoma. Patients' medical records were examined for medical comorbidities, coagulopathy, and medication list, with particular attention to any usage of SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs).</p><p><strong>Results: </strong>Twenty-two percent of patients were taking SSRIs or SNRIs. We observed a total hematoma (major + minor) rate of 1.95% for non-SSRI/SNRI users vs 1.72% for SSRI/SNRI users. The minor hematoma rate was 1.95% among nonusers vs 0% for users. The major hematoma rate was 0% among nonusers vs 1.72% for users.</p><p><strong>Conclusions: </strong>Usage of SSRIs was more common in this large series of face-lift patients than in the general population. In these patients, SSRIs in the perioperative period are found to be safe and did not seem to adversely affect outcome. We found no evidence to support discontinuing SSRIs perioperatively.</p>","PeriodicalId":55470,"journal":{"name":"Archives of Facial Plastic Surgery","volume":"14 4","pages":"248-52"},"PeriodicalIF":0.0000,"publicationDate":"2012-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archfacial.2012.2","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Facial Plastic Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/archfacial.2012.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 19

Abstract

Objective: To determine the rate of post-face-lift hematoma among users of serotonin reuptake inhibitors (SSRIs) vs non-SSRI users. Selective serotonin reuptake inhibitors have come under recent scrutiny because of possible bleeding risks. However, cessation of SSRIs carries inherent risks.

Methods: The medical charts for 250 consecutive patients who underwent a modified deep-plane face-lift and 13 patients who underwent neck-lift from January 2010 to May 2011 were reviewed for the incidence of postoperative hematoma. Patients' medical records were examined for medical comorbidities, coagulopathy, and medication list, with particular attention to any usage of SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs).

Results: Twenty-two percent of patients were taking SSRIs or SNRIs. We observed a total hematoma (major + minor) rate of 1.95% for non-SSRI/SNRI users vs 1.72% for SSRI/SNRI users. The minor hematoma rate was 1.95% among nonusers vs 0% for users. The major hematoma rate was 0% among nonusers vs 1.72% for users.

Conclusions: Usage of SSRIs was more common in this large series of face-lift patients than in the general population. In these patients, SSRIs in the perioperative period are found to be safe and did not seem to adversely affect outcome. We found no evidence to support discontinuing SSRIs perioperatively.

整容手术后抗抑郁药物和出血风险。
目的:确定5 -羟色胺再摄取抑制剂(SSRIs)使用者与非ssri使用者的面部拉皮术后血肿率。选择性5 -羟色胺再摄取抑制剂由于可能的出血风险而受到最近的审查。然而,停用ssri类药物有其固有的风险。方法:回顾2010年1月至2011年5月连续250例改良深平面面部拉皮术患者和13例颈部拉皮术患者的病历,了解术后血肿的发生情况。检查患者的医疗记录是否有合并症、凝血功能障碍和药物清单,特别注意SSRIs或5 -羟色胺去甲肾上腺素再摄取抑制剂(SNRIs)的使用情况。结果:22%的患者正在服用SSRIs或SNRIs。我们观察到,非SSRI/SNRI患者的总血肿(严重+轻微)率为1.95%,而SSRI/SNRI患者为1.72%。轻度血肿率在非服用者中为1.95%,在服用者中为0%。非使用者的主要血肿率为0%,使用者为1.72%。结论:ssri类药物的使用在这一系列的整容患者中比在普通人群中更常见。在这些患者中,SSRIs在围手术期被发现是安全的,似乎没有对结果产生不利影响。我们没有发现支持围手术期停用SSRIs的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
2 months
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信